SANGAMO THERAPEUTICS, INC.: basic earnings per share

What this measure means

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Exact concept: us-gaap:EarningsPerShareBasic. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2019-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.

Reading these values

This selected numerical history matches Diluted earnings per share for the same reporting intervals and original units. The accounting definitions remain distinct. Equal values do not establish that the concepts are interchangeable or explain why they match; filing dates and accessions may differ. Compare the definitions and source filings before combining them.

Context from the filing

For Sangamo Therapeutics in 2021 and 2022, diluted loss per share excludes anti-dilutive options, restricted stock units and employee purchase-plan shares. The 2021 numerator is loss attributable to Sangamo stockholders ($178.286 million), after excluding $11,000 of non-controlling-interest loss. The statement displays weighted-average shares in thousands; inline scale 3 supports the full share counts. Reported USD EPS and historical periods are retained. Read the source filing.

For Sangamo Therapeutics in 2024 and 2025, the filing excludes 50.5 million and 96.5 million potential shares, respectively, because their inclusion would be anti-dilutive during losses. Basic and diluted loss per share therefore use the same weighted-average shares. The statement displays share counts in thousands and inline tags use scale 3; full share counts and reported USD EPS are retained. Read the source filing.

Selected filing history

Related financial histories

• SANGAMO THERAPEUTICS, INC.: total assets
• SANGAMO THERAPEUTICS, INC.: total liabilities
• SANGAMO THERAPEUTICS, INC.: stockholders equity
• SANGAMO THERAPEUTICS, INC.: cash and cash equivalents
• SANGAMO THERAPEUTICS, INC.: net income or loss
• SANGAMO THERAPEUTICS, INC.: operating cash flow
• SANGAMO THERAPEUTICS, INC.: capital expenditure payments
• SANGAMO THERAPEUTICS, INC.: revenue
• SANGAMO THERAPEUTICS, INC.: contract revenue excluding tax
• SANGAMO THERAPEUTICS, INC.: financing cash flow
• SANGAMO THERAPEUTICS, INC.: investing cash flow
• SANGAMO THERAPEUTICS, INC.: retained earnings or deficit
• SANGAMO THERAPEUTICS, INC.: basic weighted-average shares
• SANGAMO THERAPEUTICS, INC.: diluted weighted-average shares
• SANGAMO THERAPEUTICS, INC.: diluted earnings per share
• SANGAMO THERAPEUTICS, INC.: income tax expense or benefit
• SANGAMO THERAPEUTICS, INC.: net property, plant and equipment
• SANGAMO THERAPEUTICS, INC.: share-based compensation expense
• SANGAMO THERAPEUTICS, INC.: operating income or loss
• SANGAMO THERAPEUTICS, INC.: current assets
• SANGAMO THERAPEUTICS, INC.: current liabilities
• SANGAMO THERAPEUTICS, INC.: current accounts payable
• SANGAMO THERAPEUTICS, INC.: goodwill carrying amount
• SANGAMO THERAPEUTICS, INC.: net current accounts receivable
• SANGAMO THERAPEUTICS, INC.: operating expenses
• SANGAMO THERAPEUTICS, INC.: research and development expense

Inspect the source

Entity

SANGAMO THERAPEUTICS, INC. / CIK 0001001233

Captured

2026-09-20T05:11:11.650Z

SEC response SHA-256

f678a4cd3364c095e387026eb9f115ac294a4697b3c5aebe6c86663002f694af

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001001233.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))